License And Collaboration Agreements (Commercial Products) (Narrative 1) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended		1 Months Ended	3 Months Ended	0 Months Ended	3 Months Ended		9 Months Ended	0 Months Ended	3 Months Ended
	Mar. 31, 2013 year_of_agreement	Mar. 31, 2012	Dec. 31, 2012 Voltaren Gel [Member]	Mar. 31, 2013 Voltaren Gel [Member]	Mar. 04, 2008 Voltaren Gel Agreement [Member]	Mar. 31, 2013 Voltaren Gel Agreement [Member] successive_term	Mar. 31, 2012 Voltaren Gel Agreement [Member]	Dec. 31, 2012 Voltaren Gel Agreement [Member]	Mar. 04, 2008 Voltaren Gel Agreement [Member] Voltaren Gel [Member]	Mar. 31, 2013 Voltaren Gel Agreement Extending Through June Two Thousand Twelve [Member] Novartis Consumer Health Inc [Member]	Mar. 31, 2013 Voltaren Gel Agreement Extending Through June Two Thousand Thirteen [Member] Novartis Consumer Health Inc [Member]
License And Collaboration Agreements [Line Items]
License agreement term (years)					5 years
Upfront cash payment					$ 85.0
Guaranteed minimum annual royalty payments in the fourth year					30
Guaranteed minimum annual royalty payments in the fifth year						30
Fourth year of agreement	4
Fifth year of agreement	5
Conditional milestone payment									25
Sales thresholds									300
Fair value of exclusive license									129
Guaranteed minimum royalty payment							7.5
Estimated life of license agreement (years)	15 years				5 years
Payments for royalties						7.5		21.6
Agreement expiration date						June 30, 2013
Option to extend agreement, number of terms						3
Option to extend agreement, length of successive terms						1 year
License agreement term extension				1 year
Royalty guarantees, commitments, amount			21.3
Number of months required for cancellation in renewal period						6 months
Termination of agreement notice period (days)						90 days
Long Term Purchase Commitment Percentage										13.00%
Long-term Purchase Commitment, Amount										16.0	4.5
Marketing and Advertising Expense	$ 2.1	$ 3.6